{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:45:21Z","timestamp":1790858721295,"version":"4.1.0"},"reference-count":253,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009438","name":"National Center of Neurology and Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ebiom.2019.06.036","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T16:36:52Z","timestamp":1561653412000},"page":"630-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"special_numbering":"C","title":["Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases"],"prefix":"10.1016","volume":"45","author":[{"given":"Maria K.","family":"Tsoumpra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin'ichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-7506","authenticated-orcid":false,"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2019.06.036_bb0005","first-page":"261","article-title":"Duchenne muscular dystrophy","volume":"5","author":"Dickson","year":"1995","journal-title":"Mol Cell Biol Hum Dis Ser"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases-A world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","article-title":"Duchenne and Becker Muscular Dystrophies","volume":"32","author":"Flanigan","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","article-title":"The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and othe","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0030","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/jpc.12868","article-title":"Duchenne muscular dystrophy","volume":"51","author":"Yiu","year":"2015","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.21037\/jss.2016.08.05","article-title":"Duchenne muscular dystrophy: the management of scoliosis","volume":"2","author":"Archer","year":"2016","journal-title":"J Spine Surg"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/1087057115586535","article-title":"Drug discovery of therapies for duchenne muscular dystrophy","volume":"20","author":"Blat","year":"2015","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0045","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000358439","article-title":"Severe metabolic acidosis in adult patients with duchenne muscular dystrophy","volume":"87","author":"Lo Cascio","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0050","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1164\/rccm.200503-322OC","article-title":"Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy","volume":"172","author":"Kohler","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0055","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4330\/wjc.v7.i7.410","article-title":"Cardiac involvement in Duchenne and Becker muscular dystrophy","volume":"7","author":"Mavrogeni","year":"2015","journal-title":"World J Cardiol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JND-160194","article-title":"Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy","volume":"4","author":"Fayssoil","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0065","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1152\/jn.00248.2016","article-title":"Cognitive dysfunction in Duchenne muscular dystrophy: a possible role for neuromodulatory immune molecules","volume":"116","author":"Rae","year":"2016","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.nmd.2017.11.018","article-title":"Cognitive profile in Duchenne muscular dystrophy boys without intellectual disability: The role of executive functions","volume":"28","author":"Battini","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191164","article-title":"Implicit learning deficit in children with Duchenne muscular dystrophy: Evidence for a cerebellar cognitive impairment?","volume":"13","author":"Vicari","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0080","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0085","first-page":"229","article-title":"Current treatment of adult Duchenne muscular dystrophy","volume":"2007","author":"Wagner","year":"1772","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0090","first-page":"121","article-title":"Improvement of survival in Duchenne Muscular Dystrophy: Retrospective analysis of 835 patients","volume":"31","author":"Passamano","year":"2012","journal-title":"Acta Myol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cupe.2005.04.001","article-title":"The multidisciplinary management of Duchenne muscular dystrophy","volume":"15","author":"Bushby","year":"2005","journal-title":"Curr Paediatr"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng0493-283","article-title":"The structural and functional diversity of dystrophin","volume":"3","author":"Ahn","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1006\/geno.1993.1225","article-title":"Exon Structure of the Human Dystrophin Gene","volume":"16","author":"Roberts","year":"1993","journal-title":"Genomics"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0110","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/330754a0","article-title":"Subcellular fractionation of dystrophin to the triads of skeletal muscle","volume":"330","author":"Hoffman","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ana.410380315","article-title":"Deficiency of brain synaptic dystrophin in human duchenne muscular dystrophy","volume":"38","author":"Kim","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0120","first-page":"635","article-title":"Dystrophin complex functions as a scaffold for signalling proteins","volume":"2014","author":"Constantin","year":"1838","journal-title":"Biochim Biophys Acta - Biomembr"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0125","first-page":"498","article-title":"The molecular basis for duchenne versus becker muscular dystrophy: correlation of severity with type of deletion","volume":"45","author":"Koenig","year":"1989","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00205170","article-title":"Detection of 98% of DMD\/BMD gene deletions by polymerase chain reaction","volume":"86","author":"Beggs","year":"1990","journal-title":"Hum Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The importance of genetic diagnosis for Duchenne muscular dystrophy","volume":"53","author":"Aartsma-Rus","year":"2016","journal-title":"J Med Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/15216540212333","article-title":"Muscular dystrophy: from gene diagnosis to molecular therapy","volume":"53","author":"Duchenne","year":"2002","journal-title":"IUBMB Life (International Union Biochem Mol Biol Life)"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0145","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: Structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0160","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1073\/pnas.89.6.2331","article-title":"Point mutations in the dystrophin gene","volume":"89","author":"Roberts","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12881-016-0318-y","article-title":"Duchenne muscular dystrophy caused by a frame-shift mutation in the acceptor splice site of intron 26","volume":"17","author":"Meregalli","year":"2016","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0170","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s004390100598","article-title":"Long mutant dystrophins and variable phenotypes: Evasion of nonsense-mediated decay?","volume":"109","author":"Kerr","year":"2001","journal-title":"Hum Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0175","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of dystrophin disrupts Skeletal muscle signaling: roles of Ca 2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0185","first-page":"1","article-title":"The pathophysiological role of impaired calcium handling in muscular dystrophy","author":"Ohlendieck","year":"2000","journal-title":"Bookshelf"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0190","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.biocel.2008.08.033","article-title":"Regenerative pharmacology in the treatment of genetic diseases: The paradigm of muscular dystrophy","volume":"41","author":"Mozzetta","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2005.05.010","article-title":"Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche","volume":"122","author":"Collins","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0200","first-page":"184","article-title":"The role of fibrosis in Duchenne muscular dystrophy","volume":"31","author":"Klingler","year":"2012","journal-title":"Acta Myol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0205","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1113\/expphysiol.2010.053025","article-title":"Progress in therapy for Duchenne muscular dystrophy","volume":"96","author":"Fairclough","year":"2011","journal-title":"Exp Physiol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0210","doi-asserted-by":"crossref","first-page":"9142","DOI":"10.1073\/pnas.93.17.9142","article-title":"Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0215","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0092-8674(95)90471-9","article-title":"Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy","volume":"82","author":"Brenman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0220","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.39.8.1011","article-title":"Improved diagnosis of Becker muscular dystrophy by dystrophin testing","volume":"39","author":"Hoffman","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/mt.2010.219","article-title":"The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy","volume":"19","author":"Lu","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0230","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0960-8966(94)90002-7","article-title":"Expression of dystrophin-associated proteins in dystrophin-positive muscle fibers (revertants) in Duchenne muscular dystrophy","volume":"4","author":"Matsumura","year":"1994","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10974-011-9238-9","article-title":"Biomechanics of the sarcolemma and costameres in single skeletal muscle fibers from normal and dystrophin-null mice","volume":"31","author":"Garc\u00eda-Pelagio","year":"2011","journal-title":"J Muscle Res Cell Motil"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0245","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0250","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1172\/JCI115244","article-title":"Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy Kobe","volume":"87","author":"Matsuo","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0255","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0006-291X(90)92185-3","article-title":"A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene","volume":"170","author":"Matsuo","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0260","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0387-7604(96)00007-1","article-title":"Duchenne\/Becker muscular dystrophy: from molecular diagnosis to gene therapy","volume":"18","author":"Matsuo","year":"1996","journal-title":"Brain Dev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0265","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0270","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/j.biocel.2013.05.001","article-title":"Wasting mechanisms in muscular dystrophy","volume":"45","author":"Shin","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0275","series-title":"Translational Research in Muscular Dystrophy","first-page":"87","article-title":"Translational research in nucleic acid therapies for muscular dystrophies","author":"Lee","year":"2016"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0280","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0285","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/wrna.1158","article-title":"Targeting RNA splicing for disease therapy","volume":"4","author":"Havens","year":"2013","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/ard.1991.1.141","article-title":"Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2032 exonuclease in plasma","volume":"1","author":"Eder","year":"1991","journal-title":"Antisense Res Dev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0295","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/402369","article-title":"Development of multiexon skipping antisense oligonucleotide therapy for duchenne muscular dystrophy","author":"Aoki","year":"2013","journal-title":"Biomed Res Int"},{"issue":"22","key":"10.1016\/j.ebiom.2019.06.036_bb0300","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1093\/nar\/25.22.4429","article-title":"The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes","volume":"25","author":"Freier","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0305","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0310","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1440-1789.2009.01028.x","article-title":"Exon-skipping therapy for Duchenne muscular dystrophy","volume":"29","author":"Nakamura","year":"2009","journal-title":"Neuropathology"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0315","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","author":"Rinaldi","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0320","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0325","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino antissense oligomers: design, preparation, and properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0330","first-page":"93","article-title":"Antisense treatments for biothreat agents","volume":"8","author":"Warfield","year":"2006","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0335","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.ddstr.2013.04.001","article-title":"Antisense oligonucleotides as personalized medicine for Duchenne muscular dystrophy","volume":"10","author":"van Deutekom","year":"2013","journal-title":"Drug Discov Today Ther Strateg"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0340","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1006\/bbrc.1997.7328","article-title":"Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in duchenne muscular dystrophy","volume":"238","author":"Araki","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/s41536-018-0045-4","article-title":"Humanizing the mdx mouse model of DMD: the long and the short of it","author":"Yucel","year":"2018","journal-title":"npj Regen Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0350","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/jgm.603","article-title":"Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): Target sequence optimisation using oligonucleotide arrays","volume":"6","author":"Graham","year":"2004","journal-title":"J Gene Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0355","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1073\/pnas.98.1.42","article-title":"Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse","volume":"98","author":"Mann","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0360","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajpath.2012.04.006","article-title":"Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino","volume":"181","author":"Wu","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0365","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1073\/pnas.0406700102","article-title":"Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles","volume":"102","author":"Lu","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0370","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/hmg\/ddg196","article-title":"Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle","volume":"12","author":"Gebski","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0375","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0380","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/mt.2010.186","article-title":"In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse","volume":"18","author":"Aoki","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0385","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","article-title":"Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-\u03b12 chain-null congenital muscular dystrophy mice","volume":"22","author":"Aoki","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0390","doi-asserted-by":"crossref","first-page":"13763","DOI":"10.1073\/pnas.1204638109","article-title":"Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery","volume":"109","author":"Aoki","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0395","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1096\/fj.06-7353com","article-title":"Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma","volume":"21","author":"Chamberlain","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0400","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.38","article-title":"Long-term exon skipping studies with 2'-o-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models","volume":"1","author":"Tanganyika-De Winter","year":"2012","journal-title":"Mol Ther - Nucleic Acids"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0405","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/sj.gt.3302800","article-title":"Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD","volume":"13","author":"McClorey","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0410","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.21627","article-title":"Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs","volume":"65","author":"Yokota","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2018.10.011","article-title":"Efficacy of multi-exon skipping treatment in duchenne muscular dystrophy dog model neonates","author":"Lim","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0420","doi-asserted-by":"crossref","DOI":"10.3791\/53776","article-title":"Multi-exon skipping using cocktail antisense oligonucleotides in the canine X-linked muscular dystrophy","author":"Miskew Nichols","year":"2016","journal-title":"J Vis Exp"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0425","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: a first in class strategy for Duchenne muscular dystrophy","volume":"17","author":"Niks","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0430","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne's muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0435","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): An exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0440","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy","volume":"28","author":"Goemans","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0445","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2016.16437","article-title":"Approving a problematic muscular dystrophy drug","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0450","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/21678707.2017.1366310","article-title":"Clinical trials of exon skipping in Duchenne muscular dystrophy","volume":"5","author":"Mendell","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0455","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0460","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0465","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.nmd.2017.06.442","article-title":"WVE-210201, an investigational stereopure oligonucleotide therapy for Duchenne muscular dystrophy, induces Exon 51 skipping and dystrophin protein restoration","volume":"27","author":"Wood","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0470","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jns.2017.08.791","article-title":"Preclinical studies of WVE-210201, an investigational stereopure antisense oligonucleotide in development for the treatment of patients with duchenne muscular dystrophy (DMD)","volume":"381","author":"Panzara","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0475","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0480","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.S42.001","article-title":"Eteplirsen for the treatment of duchenne muscular dystrophy (DMD)","volume":"88","author":"Charleston","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0485","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0490","first-page":"1","article-title":"In vivo delivery of morpholino oligos as therapeutics: what barriers still exist ?","volume":"3","author":"Yong-fu","year":"2016","journal-title":"J Drug Discov Dev Deliv"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0495","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/jhg.2017.57","article-title":"Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy","volume":"62","author":"Nakamura","year":"2017","journal-title":"J Hum Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0500","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines6010001","article-title":"Skipping multiple exons to treat DMD\u2014promises and challenges","volume":"6","author":"Aslesh","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0510","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajpath.2011.03.050","article-title":"Restoring dystrophin expression in duchenne muscular dystrophy muscle","volume":"179","author":"Hoffman","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0515","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.6","article-title":"What can we learn from clinical trials of exon skipping for DMD?","volume":"3","author":"Lu","year":"2014","journal-title":"Mol Ther - Nucleic Acids"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0525","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cell.2016.10.050","article-title":"Exon skipping therapy","volume":"167","author":"Young","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2017.10.082","article-title":"Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis","volume":"49","author":"Randeree","year":"2018","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0535","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/mt.2016.188","article-title":"Eteplirsen approved for duchenne muscular dystrophy: the FDA faces a difficult choice","volume":"24","author":"Stein","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0540","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1177\/1352458516688349","article-title":"Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study","volume":"23","author":"Gonz\u00e1lez Torre","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0545","doi-asserted-by":"crossref","first-page":"eaan0713","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0550","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.S22.001","article-title":"Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in duchenne muscular dystrophy patients with mutations amenable to Exon 53 skipping (S22.001)","volume":"90","author":"Muntoni","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0555","doi-asserted-by":"crossref","first-page":"25ps15","DOI":"10.1126\/scitranslmed.3000512","article-title":"Toward an oligonucleotide therapy for duchenne muscular dystrophy: a complex development challenge","volume":"2","author":"Wood","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0560","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0565","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.04976.x","article-title":"Peptide-morpholino conjugate: a promising therapeutic for duchenne muscular dystrophy","volume":"1175","author":"Moulton","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0570","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mcn.2013.04.005","article-title":"Splicing therapy for neuromuscular disease","volume":"56","author":"Douglas","year":"2013","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2019.01.008","article-title":"Scavenger receptor Class A1 mediates uptake of morpholino antisense oligonucleotide into dystrophic skeletal muscle","author":"Miyatake","year":"2019","journal-title":"Mol Ther - Nucleic Acids"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0580","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.25.12.1111","article-title":"Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber","volume":"25","author":"Mokri","year":"1975","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0585","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/mt.2010.261","article-title":"Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice","volume":"19","author":"Malerba","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0590","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/molecules14031304","article-title":"Gene knockdowns in adult animals: PPMOs and vivo-morpholinos","volume":"14","author":"Moulton","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0595","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1196\/annals.1359.012","article-title":"Endo-Porter: a novel reagent for safe, effective delivery of substances into cells","volume":"1058","author":"Summerton","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0600","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2144\/000113005","article-title":"Vivo-morpholinos: a non-peptide transporter delivers morpholinos into a wide array of mouse tissues","volume":"45","author":"Morcos","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0605","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/mt.2009.38","article-title":"Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice","volume":"17","author":"Wu","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0610","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1089\/nat.2012.0368","article-title":"Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs","volume":"22","author":"Yokota","year":"2012","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0615","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.76","article-title":"Long-term efficacy of systemic multiexon skipping targeting Dystrophin exons 45-55 with a cocktail of vivo-morpholinos in Mdx52 mice","volume":"4","author":"Echigoya","year":"2015","journal-title":"Mol Ther - Nucleic Acids"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0620","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0625","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00018-009-0186-0","article-title":"Cell penetrating peptides: overview and applications to the delivery of oligonucleotides","volume":"67","author":"Said Hassane","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0630","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/108729003764097322","article-title":"HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers","volume":"13","author":"Moulton","year":"2003","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0635","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.mt.6300329","article-title":"Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice","volume":"16","author":"Yin","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0640","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/bc034221g","article-title":"Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides","volume":"15","author":"Moulton","year":"2004","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0645","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1074\/jbc.M209548200","article-title":"Cell-penetrating peptides: a reevaluation of the mechanism of cellular uptake","volume":"278","author":"Richard","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0650","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1093\/nar\/gkn541","article-title":"Delivery of steric block morpholino oligomers by (R-X-R)4peptides: structure-activity studies","volume":"36","author":"Abes","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0655","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1034\/j.1399-3011.2000.00723.x","article-title":"Polyarginine enters cells more efficiently than other polycationic homopolymers","volume":"56","author":"Mitchell","year":"2000","journal-title":"J Pept Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0660","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1093\/nar\/gkn671","article-title":"Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle","volume":"36","author":"Ivanova","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0665","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1093\/nar\/gkm418","article-title":"Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide","volume":"35","author":"Abes","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0670","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/bc060138s","article-title":"Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells","volume":"18","author":"Youngblood","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0675","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide - Morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0680","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2006.09.011","article-title":"Vectorization of morpholino oligomers by the (R-Ahx-R)4peptide allows efficient splicing correction in the absence of endosomolytic agents","volume":"116","author":"Abes","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0685","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.addr.2016.06.008","article-title":"Peptides for nucleic acid delivery","volume":"106","author":"Lehto","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0690","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.addr.2007.09.003","article-title":"Predicting cell-penetrating peptides","volume":"60","author":"Hansen","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0695","article-title":"Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents","volume":"38","author":"Stein","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0700","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-61779-424-7_25","article-title":"Silencing of gene expression by gymnotic delivery of antisense oligonucleotides","volume":"815","author":"Soifer","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0705","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1021\/acs.nanolett.5b00490","article-title":"Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides","volume":"15","author":"Ezzat","year":"2015","journal-title":"Nano Lett"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0710","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","article-title":"Cellular uptake and intracellular trafficking of oligonucleotides","volume":"87","author":"Juliano","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0715","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/nat.2016.0641","article-title":"Intracellular distribution and nuclear activity of antisense oligonucleotides after unassisted uptake in myoblasts and differentiated myotubes in vitro","volume":"27","author":"Gonz\u00e1lez-Barriga","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0720","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0725","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.2174\/13816128113199990297","article-title":"Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles","volume":"19","author":"Cleal","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0730","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0735","first-page":"2296","article-title":"Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"2010","author":"Moulton","year":"1798","journal-title":"Biochim Biophys Acta - Biomembr"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0740","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1096\/fj.11-191536","article-title":"Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides","volume":"26","author":"Ezzat","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0745","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.88.5.1864","article-title":"Antennapedia homeobox peptide regulates neural morphogenesis","volume":"88","author":"Joliot","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0750","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/mt.2011.79","article-title":"Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice","volume":"19","author":"Yin","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0755","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt1220","article-title":"Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells","volume":"42","author":"Lehto","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0760","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15252\/emmm.201607199","article-title":"Delivery is key: lessons learnt from developing splice-switching antisense therapies","volume":"9","author":"Godfrey","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0765","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jconrel.2005.10.026","article-title":"Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates","volume":"110","author":"Abes","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0770","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1021\/acs.bioconjchem.7b00560","article-title":"Unlocking Endosomal Entrapment with Supercharged Arginine-Rich Peptides","volume":"28","author":"Najjar","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0775","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/hmg\/ddw201","article-title":"Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles","volume":"25","author":"Peccate","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0780","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0092-8674(00)80532-2","article-title":"Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy","volume":"90","author":"Deconinck","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0785","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/mt.2009.248","article-title":"Prevention of dystrophic pathology in severely affected dystrophin\/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping","volume":"18","author":"Goyenvalle","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0790","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/gt.2014.53","article-title":"Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice","volume":"21","author":"Wu","year":"2014","journal-title":"Gene Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0795","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/mt.2008.120","article-title":"Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice","volume":"16","author":"Jearawiriyapaisarn","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0800","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","article-title":"Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function","volume":"17","author":"Yin","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0805","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1093\/hmg\/ddp395","article-title":"A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice","volume":"18","author":"Yin","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0810","doi-asserted-by":"crossref","first-page":"14814","DOI":"10.1073\/pnas.0805676105","article-title":"Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer","volume":"105","author":"Wu","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0815","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2014.63","article-title":"Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice","volume":"22","author":"Gao","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0820","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrd3459","article-title":"Targeting RNA to treat neuromuscular disease","volume":"10","author":"Muntoni","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0825","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol Ther - Nucleic Acids"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0830","doi-asserted-by":"crossref","DOI":"10.1038\/srep08986","article-title":"Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice","volume":"5","author":"Betts","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0835","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1073\/pnas.1613203114","article-title":"Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy","volume":"114","author":"Echigoya","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0840","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/nat.2013.0448","article-title":"Peptide conjugation of 2\u2032- O -methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice","volume":"24","author":"Jirka","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0845","first-page":"1","article-title":"Cyclic peptides to improve delivery and exon skipping of antisense oligonucleotides in a mouse model for duchenne muscular dystrophy","volume":"26","author":"Jirka","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0850","doi-asserted-by":"crossref","DOI":"10.1152\/japplphysiol.00833.2013","article-title":"Diaphragm remodeling and compensatory respiratory mechanics in a canine model of Duchenne muscular dystrophy","volume":"116","author":"Mead","year":"2014","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0855","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/352536a0","article-title":"The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy","volume":"352","author":"Stedman","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0860","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1042\/BST0350826","article-title":"Cell-penetrating peptide\u2013morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo","volume":"35","author":"Moulton","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0865","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.mt.6300245","article-title":"Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse","volume":"15","author":"Fletcher","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0870","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2010.151","article-title":"Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO","author":"Yin","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0875","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/hmg\/ddq477","article-title":"Diaphragm rescue alone prevents heart dysfunction in dystrophic mice","volume":"20","author":"Crisp","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep11632","article-title":"Implications for cardiac function following rescue of the dystrophic diaphragm in a mouse model of duchenne muscular dystrophy","volume":"5","author":"Betts","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0885","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-G","article-title":"The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy","volume":"26","author":"Nigro","year":"1990","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0890","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000068446","article-title":"The heart in human dystrophinopathies","volume":"99","author":"Finsterer","year":"2003","journal-title":"Cardiology"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0895","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/gt.2009.120","article-title":"Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino","volume":"17","author":"Wu","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0900","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/mt.2010.288","article-title":"One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice","volume":"19","author":"Wu","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0905","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","article-title":"Preclinical PK and PD studies on 2\u2032-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model","volume":"18","author":"Heemskerk","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0910","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.nmd.2008.05.011","article-title":"In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle","volume":"18","author":"Vitiello","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0915","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/nat.2011.0306","article-title":"Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity","volume":"21","author":"Malerba","year":"2011","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0920","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/mt.2008.52","article-title":"Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle","volume":"16","author":"Townsend","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0925","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/cvr\/cvp335","article-title":"Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers","volume":"85","author":"Jearawiriyapaisarn","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0930","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.it.2008.05.002","article-title":"Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression","volume":"29","author":"Gao","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0935","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1242\/dmm.030205","article-title":"Neurodegenerative disease: models, mechanisms, and a new hope","volume":"10","author":"Gitler","year":"2017","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0940","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nature20411","article-title":"Ageing, neurodegeneration and brain rejuvenation","volume":"539","author":"Wyss-Coray","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0945","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2016.03.020","article-title":"Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems","volume":"229","author":"Zhang","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0950","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","article-title":"Progress and perspectives on targeting nanoparticles for brain drug delivery","volume":"6","author":"Gao","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0955","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.coph.2006.04.004","article-title":"Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery","volume":"6","author":"M\u00e4e","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0960","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139652","article-title":"Cell-penetrating peptides selectively cross the blood-brain barrier in vivo","volume":"10","author":"Stalmans","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0970","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1570159X11311020006","article-title":"Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system","volume":"11","author":"Zou","year":"2013","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0975","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1523\/JNEUROSCI.22-13-05423.2002","article-title":"In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury andneuronal apoptosis","volume":"22","author":"Cao","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0980","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/nat.2016.0652","article-title":"Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy","volume":"27","author":"Shabanpoor","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0985","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/hmg\/ddr217","article-title":"Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum","volume":"20","author":"Du","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0990","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrneurol.2015.77","article-title":"Spinal muscular atrophy\u2014recent therapeutic advances for an old challenge","volume":"11","author":"Faravelli","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb0995","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1000","doi-asserted-by":"crossref","DOI":"10.1038\/ng0598-63","article-title":"SMN oligomerization defect correlates with spinal muscular atrophy severity","author":"Lorson","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1005","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.01262-08","article-title":"Regulation of SMN protein stability","author":"Burnett","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1015","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M107632200","article-title":"Modulation of survival motor neuron Pre-mRNA splicing by inhibition of alternative 3\u2032 splice site pairing","author":"Lim","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1020","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/molecules22040563","article-title":"Antisense oligonucleotide-based therapy for neuromuscular disease","volume":"22","author":"Sardone","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1040","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1045","doi-asserted-by":"crossref","DOI":"10.1177\/1756285618754501","article-title":"Advances in spinal muscular atrophy therapeutics","volume":"11","author":"Parente","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1050","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1055","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1038\/s41598-018-22316-7","article-title":"Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis","volume":"8","author":"van der Bent","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington\u2019s disease: time-dependent alterations in synaptic and receptor function","volume":"198","author":"Raymond","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1065","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1070","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1093\/hmg\/ddu349","article-title":"Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity","volume":"23","author":"Sun","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1075","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1111\/jcmm.13209","article-title":"Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington\u2019s disease","volume":"21","author":"Chen","year":"2017","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1080","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.CT.002","article-title":"Effects of IONIS-HTTRx in patients with early Huntington's disease, results of the first HTT-lowering drug trial (CT.002)","volume":"90","author":"Tabrizi","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"2","author":"Brown","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1090","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2013.00253","article-title":"An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis","volume":"7","author":"Rotunno","year":"2013","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jnnp-2016-313521","article-title":"Defining SOD1 ALS natural history to guide therapeutic clinical trial design","volume":"88","author":"Bali","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1110","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1115","doi-asserted-by":"crossref","DOI":"10.1038\/srep21301","article-title":"Morpholino-mediated SOD1 reduction ameliorates an amyotrophic lateral sclerosis disease phenotype","volume":"6","author":"Nizzardo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1120","doi-asserted-by":"crossref","first-page":"E4530","DOI":"10.1073\/pnas.1318835110","article-title":"Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration","volume":"110","author":"Lagier-Tourenne","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1125","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","article-title":"Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide","volume":"2","author":"Henry","year":"2002","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1130","article-title":"Humoral and cell mediated immune response to new dystrophin after morpholino-induced exon skipping therapy in dystrophin-deficient mdx mice","author":"Nagaraju","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1135","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nbt759","article-title":"Systemically delivered antisense oligomers upregulate gene expression in mouse tissues","volume":"20","author":"Sazani","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1091581811403505","article-title":"Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy","volume":"30","author":"Sazani","year":"2011","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxrep.2015.05.008","article-title":"The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse","author":"Zhang","year":"2015","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1150","article-title":"Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment","author":"Gait","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0300-483X(97)03661-5","article-title":"Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys","volume":"120","author":"Henry","year":"1997","journal-title":"Toxicology"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/nat.2014.0528","article-title":"Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides","volume":"25","author":"Burki","year":"2015","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1165","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/hum.2008.157","article-title":"Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon Skipping in mdx mice","volume":"20","author":"Malerba","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/965631","article-title":"Understanding the process of fibrosis in duchenne muscular dystrophy","volume":"2014","author":"Kharraz","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1175","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mt.2008.287","article-title":"Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene","volume":"17","author":"Popplewell","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120058","article-title":"In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in duchenne muscular dystrophy","volume":"10","author":"Echigoya","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1185","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/jhg.2016.28","article-title":"Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy","volume":"61","author":"Nakamura","year":"2016","journal-title":"J Hum Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1190","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/jhg.2016.152","article-title":"Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy","volume":"62","author":"Nakamura","year":"2017","journal-title":"J Hum Genet"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1195","article-title":"Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101722","article-title":"Endogenous multiple exon skipping and back-splicing at the DMD mutation hotspot","volume":"17","author":"Suzuki","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1205","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.12688\/f1000research.8735.1","article-title":"Advances in gene therapy for muscular dystrophies","volume":"5","author":"Abdul-Razak","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1210","first-page":"179","article-title":"Optimizing exon skipping therapies for DMD","volume":"26","author":"Yokota","year":"2007","journal-title":"Acta Myol Myopathies Cardiomyopathies"},{"issue":"5","key":"10.1016\/j.ebiom.2019.06.036_bb1215","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of exon skipping therapies for duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/jpm7040013","article-title":"Immortalized muscle cell model to test the exon skipping efficacy for duchenne muscular dystrophy","volume":"7","author":"Nguyen","year":"2017","journal-title":"J Pers Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1225","doi-asserted-by":"crossref","DOI":"10.1002\/emmm.201100133","article-title":"miRNAs as serum biomarkers for Duchenne muscular dystrophy","author":"Cacchiarelli","year":"2011","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1230","article-title":"Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies","author":"Giordani","year":"2014","journal-title":"Rare Dis (Austin, Tex)"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1235","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.035774","article-title":"Tracking progress: an update on animal models for Duchenne muscular dystrophy","author":"Wells","year":"2018","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1240","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.03.091","article-title":"Three-dimensional human iPSC-derived artificial skeletal muscles model muscular dystrophies and enable multilineage tissue engineering","author":"Maffioletti","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2014.10.013","article-title":"Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9","author":"Li","year":"2015","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1250","series-title":"Exon Skipping and Inclusion Therapies: Methods and Protocols","article-title":"Restoration of dystrophin protein expression by exon skipping utilizing CRISPR-Cas9 in myoblasts derived from DMD patient iPS cells","author":"Ifuku","year":"2018"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1255","doi-asserted-by":"crossref","DOI":"10.1038\/srep12831","article-title":"Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells","author":"Shoji","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1260","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-015-0408-z","article-title":"Improving clinical trial design for Duchenne muscular dystrophy","author":"Merlini","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1016\/j.ebiom.2019.06.036_bb1265","article-title":"The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419304165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419304165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:56:15Z","timestamp":1762455375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419304165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":253,"alternative-id":["S2352396419304165"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.036","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}